Compare ZBRA & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZBRA | FMS |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 13.5B |
| IPO Year | 1991 | 1996 |
| Metric | ZBRA | FMS |
|---|---|---|
| Price | $264.66 | $23.73 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | ★ $346.29 | $30.00 |
| AVG Volume (30 Days) | ★ 622.0K | 450.8K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | ★ 34.78 | 8.62 |
| EPS | ★ 9.93 | 2.86 |
| Revenue | $5,255,000,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $10.26 | $2.12 |
| Revenue Next Year | $10.00 | $2.92 |
| P/E Ratio | $27.04 | ★ $15.93 |
| Revenue Growth | ★ 12.87 | 2.10 |
| 52 Week Low | $205.73 | $22.05 |
| 52 Week High | $427.76 | $30.46 |
| Indicator | ZBRA | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 48.94 |
| Support Level | $248.34 | $22.63 |
| Resistance Level | $274.27 | $23.87 |
| Average True Range (ATR) | 6.16 | 0.28 |
| MACD | 2.71 | 0.14 |
| Stochastic Oscillator | 62.92 | 83.09 |
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.